Document is current
Any future updates will be listed below
-
Authors
Hildenbrand, Jordan D. https://orcid.org/0000-0001-8462-7262
Davis, Debra M.
El-Jawahri, Areej
Herring, Kris W.
Locke, Susan C.
Pollak, Kathryn I.
Samsa, Gregory P.
Steinhauser, Karen E.
Troy, Jesse D.
Ubel, Peter A.
Leblanc, Thomas W. https://orcid.org/0000-0002-0546-7895
-
Funding
Funding for this research was provided by:
American Cancer Society (MRSG-15-185-01-PCSM)
- License Information
-
More Information
Article History
Received: 23 July 2020
Accepted: 28 October 2020
First Online: 6 November 2020
Compliance with ethical standards
:
: Dr. El-Jawahri is a Scholar in Clinical Research of the Leukemia and Lymphoma Society.Dr. LeBlanc is currently, or has recently been (last 24 months), a consultant for AbbVie, Agios, AstraZeneca, CareVive, Helsinn, Flatiron, Otsuka, Pfizer, and Seattle Genetics and has served on recent advisory boards for AbbVie, Agios, Amgen, Daiichi-Sankyo, Heron, and Otsuka. He has received honoraria from AbbVie and Celgene for non-branded speaking engagements and is a member of a speakers bureau for Agios and Celgene. He has received recent research funding from the American Cancer Society, AstraZeneca, Bristol Myers Squibb, Duke University, Jazz Pharmaceuticals, the National Institute of Nursing Research/National Institutes of Health, and Seattle Genetics.
